- PureTech Health said it had been issued with a patent in the US that supported an immuno-oncology product candidate.

The US Patent and Trademark Office had issued US Patent No. 10,344,091 to support candidate LYT-200, the company said.

The patent covered compositions of matter directed to fully human anti-galectin-9 antibodies, which PureTech intended to develop for historically difficult-to-treat cancers.

At 9:36am: [LON:PRTC] PureTech Health Plc share price was +0.5p at 231p

Story provided by